Ladiratuzumab
LadiratuzumAb (hLIV22) is a humanized monoclonal antibody targeting LIV-1/ZIP6.LadiratuzumAb is a naked antibody to SGN-LIV1A and is capable of synthesizing an antibody-activated molecule coupling (ADC), SGN-LIV1A.LadiratuzumAb can be used for the prevention and treatment of breast cancer.
Product Specifications
CAS Number
1629760-28-6
Stability
≥ 2 years
Purity
>98% (HPLC)
Molecular Formula
——
Notes
Research use only, not for human use.
Receptor
Others
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
LV768554 1.0 µg DNA
MIR3914-1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro)
Sign In for Pricing
View Details 
MBS6365301-01 0.1 mL
ZFYVE28, CT (ZFYVE28, KIAA1643, LST2, Lateral signaling target protein 2 homolog, Zinc finger FYVE domain-containing protein 28) (MaxLight 650)
Sign In for Pricing
View Details MBS6365301-02 5x 0.1 mL
ZFYVE28, CT (ZFYVE28, KIAA1643, LST2, Lateral signaling target protein 2 homolog, Zinc finger FYVE domain-containing protein 28) (MaxLight 650)
Sign In for Pricing
View Details